Sinobioway Medicine(SZ:002581) Xin Lang Cai Jing·2026-02-27 06:42Core Viewpoint - ST Unimed (SZ002581) experienced a trading halt with a price of 8.4 yuan, reflecting a 5% increase, and a total market capitalization of 5.542 billion yuan, driven by positive developments in its business operations and market conditions [1][2]. Group 1: Company Developments - The subsidiary of the company obtained a pharmaceutical operating license, which is expected to enhance its pharmaceutical industry chain layout and positively impact long-term business development [2]. - The company won a legal case to recover 34% of its equity in Xiamen Unimed and received compensation, strengthening its control over related business operations [2]. - The company's losses for 2025 narrowed by 34.46% to 59.95% year-on-year, indicating an improvement in operational conditions and effectiveness in strategic adjustments or cost control [2]. Group 2: Market and Technical Analysis - The biopharmaceutical sector showed active performance on February 27, 2026, contributing to a sector-wide momentum that benefited the company, which specializes in interferon, nerve growth factors, and vaccines [2]. - Technical indicators such as the MACD may form a golden cross, and short-term moving averages are in a bullish arrangement, suggesting potential upward momentum [2]. - There was a net inflow of large orders on that day, indicating that major funds are paying attention to and participating in the stock, which contributed to the price increase [2].